Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
•Journal Article
Diabetic Kidney Disease
TL;DR: Despite improvements in glycemic control and lower blood pressure targets, the incidence of DKD has not declined substantially and preventive measures continue to rely on glucose and blood pressure control.
PET detection of the impact of dobutamine on myocardial glucose metabolism in women with type 1 diabetes mellitus
Pilar Herrero,Janet B. McGill,Donna S. Lesniak,Carmen S. Dence,Shalonda W. Scott,Zulfia Kisrieva-Ware,Robert J. Gropler +6 more
TL;DR: In women with T1DM, myocardial glucose metabolism is impaired downstream from initial uptake, and these abnormalities become more pronounced with dobutamine and are paralleled by an increase in myocardIAL fatty acid metabolism, and insulin restores glucose metabolism to levels observed in normal control subjects.
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia.
Natalie A. Bello,Marc A. Pfeffer,Hicham Skali,Janet B. McGill,Jerome Rossert,Kurt Olson,Larry A. Weinrauch,Mark E. Cooper,Dick de Zeeuw,Peter Rossing,John J.V. McMurray,Scott D. Solomon +11 more
TL;DR: In a large cohort of patients with T2DM, CKD, and anemia, retinopathy was common but not independently associated with a higher risk of renal or cardiovascular morbidity or death.
Potentiation of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance.
Janet B. McGill,Linda R. Peterson,Pilar Herrero,Ibrahim M. Saeed,Carol Recklein,Andrew R. Coggan,Amanda J. DeMoss,Kenneth B. Schechtman,Carmen S. Dence,Robert J. Gropler +9 more
TL;DR: In women, the presence of OB and DM compared with OB alone is associated with a greater reliance on myocardial FA metabolism at the expense of glucose metabolism, suggesting that the metabolic perturbations may precede an eventual decline left ventricular function as is seen in animal models of DM.
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
TL;DR: In clinical trials, empagliflozin has demonstrated a good efficacy and safety profile in a broad range of patients with T2DM, and appears to be an attractive adjunct therapeutic option for the treatment of type 2 diabetes mellitus.